You can buy or sell AVDL and other stocks, options, ETFs, and crypto commission-free!
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. Read More The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
Form 10-K AVADEL PHARMACEUTICALS For: Dec 31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission file number: 000-28508 AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) Ireland 98-1341933 State or other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) Block 10-1, Blanchardstown Corpor...
Seeking AlphaMar 15
Avadel Pharmaceuticals (AVDL) CEO Greg Divis on Q4 2018 Results - Earnings Call Transcript
Avadel Pharmaceuticals (NASDAQ:AVDL) Q4 2018 Earnings Conference Call March 15, 2019 8:30 AM ET Company Participants Greg Divis - CEO Mike Kanan - CFO Geoff Glass - Chairman Conference Call Participants Matt Kaplan - Ladenburg Thalmann Francois Brisebois - Laidlaw Operator Good morning, ladies and gentlemen, thank you for standing by. And welcome to the Avadel Pharmaceuticals’ Fourth Quarter and Full-Year 2018 Financial Results Conference Call. At this time, all participants are in a listen-only m...
Yahoo FinanceMar 15
Avadel: 4Q Earnings Snapshot
DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Friday reported a loss of $63.9 million in its fourth quarter. The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. Scroll to continue with content Ad For the year, the company reported a loss of $95.3 million, or $2.55 per share, swinging to a loss in the period. Revenue was reported as $103.3 million. The company's shares closed at $2. A year ago, they were...
-$2.34 per share
-$0.46 per share